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Background: In England, a national breast screening programme (NHSBSP) has been in place since 1988, and
assessment of its impact on breast cancer incidence and mortality is essential to ensure that the programme is
indeed doing more good than harm. This article describes large observation studies designed to estimate the
effects of the current programme in terms of the benefits on breast cancer incidence and mortality and detrimental
effect in terms of overdiagnosis. The case-control design of the cervical screening programme evaluation was highly
effective in informing policy on screening intervals and age ranges. We propose innovative selection of cases and
controls and gathering of additional variables to address new outcomes of interest and develop new methodologies to
control for potential sources of bias.
Methods/Design: Traditional case-control evaluation of breast screening uses women who have died from breast
cancer as cases, and women known to be alive at the time of case death as controls. Breast screening histories prior to
the cases’ date of first diagnosis are compared. If breast screening is preventing mortality from breast cancer, cases will
be characterised by a lesser screening history than controls. All deaths and incident cases of primary breast cancer in
England within each 2-year study period will be included in this ongoing evaluation. Cases will be age- and area-
matched to controls and variables related to cancer treatment and breast tumour pathology will be obtained to
investigate the interplay between screening and treatment, and the effect of screening on incidence of advanced
stage disease. Screening attendance at other national screening programmes will also be collected to derive superior
adjustment for self-selection bias.
The study is registered and has received full ethics approval.
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Breast cancer is the most commonly diagnosed cancer
among women in the UK, accounting for a third of all fe-
male cancer cases, and the second most common cause of
cancer death: in England in 2010, the age-standardised
rate per 100,000 women-years was 125.7 for incidence and
24.3 for mortality; in addition, in situ breast cancer, that is
Ductal Carcinoma In Situ (DCIS) and Lobular Carcinoma
In Situ (LCIS), was diagnosed at a rate of 18 per 100,000
women in 2010 (CRUK, Accessed 28 March 2013 [1]).
In the early nineties, meta-analyses of the randomised
controlled trials (RCTs) confirmed the efficacy of mammo-
graphic screening for reducing primary breast cancer mor-
tality, and led to the implementation of breast screening* Correspondence: s.w.duffy@qmul.ac.uk
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reproduction in any medium, provided the orprogrammes in several regions of Europe. One of the most
mature and comprehensive of those is the English Na-
tional Breast Screening Programme (NHSBSP) which has
been in place in England since 1988. A major issue to be
addressed by the Department of Health’s (England) Policy
Research Unit in Cancer Awareness, Screening and Early
Diagnosis (PRU), is to evaluate the policy of mammog-
raphy screening as delivered in the current NHSBSP in
terms of benefits on mortality from and on incidence of
invasive primary breast cancer, and harms from the most
adverse outcome of breast screening. Overdiagnosis is the
detection of a breast cancer that would never have been
clinically identified in the lifetime of the woman if she had
not been screened. In the post-RCT epoch, analytical ob-
servational studies are the design of choice.
A key feature of case–control evaluation should be
that the study is nested within a well defined cohort ofLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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corded. This confers a reliability and interpretability com-
parable with a prospective evaluation. The basic premise
of the case–control audit for a screening programme is as
follows: if screening ‘works’ in preventing the relevant
clinical outcome, then those who experience the outcome
(cases) will be characterised by a lesser history of screen-
ing than those who do not (controls). Cases and controls
are compared with respect to screening history, and the
reduction in odds of the relevant clinical outcome is esti-
mated for various measures of exposure to screening by
using the ratio of the odds (Verbeek and Broeders, 2010
[2]). The traditional case–control evaluation of breast
screening takes women aged 50-70/75 years at diagnosis
as cases, who have died from primary breast cancer, and
women known to be alive at the time of death of the cases
as controls. Controls are usually matched approximately
for date of birth and, possibly, geographical area. Screening
histories prior to the date of first primary breast cancer
diagnosis of the cases are then compared between cases
and controls. Previous case–control evaluations of the
NHSBSP have been undertaken in the East Anglia and
West Midlands areas. They found that screening in the
NHSBSP was associated with a reduction in breast cancer
deaths, at least as great as that obtained in the randomised
controlled trials of mammographic screening. In the East
Anglia case–control study, the odds ratio for risk of death
from primary breast cancer in women who attended at
least one routine screen (i.e. potentially including the
screen leading to diagnosis) compared to those who did
not attend was 0.52 (95% CI: 0.32, 0.84; Allgood et al.,
2008 [3]). In the West Midlands case–control study, the
corresponding odds ratio was 0.43 (95% CI: 0.27, 0.67; All-
good, Warwick & Duffy et al., unpublished data). However,
an earlier case–control study in Wales (Fielder et al., 2004
[4]) found a more modest effect (odds ratio = 0.75, 95% CI
0.49–1.14). The design of the East Anglia and West
Midlands studies were very similar in that they identified
cases among women diagnosed since 1995 and 1994, re-
spectively, to avoid choosing cases resulting from the
accumulation at the prevalent round of the screening
programme, and to minimize exposure (screening) oppor-
tunity bias (Walter, 2003 [5]). This, however, may have in-
troduced a bias towards the inclusion of cases with short
survival (women had to have died before the end of 2004
and 2005, respectively), and consequently overestimated
the benefit of screening. In contrast, the Wales study iden-
tified cases among women diagnosed between 1991 and
2000, and was therefore dominated by prevalence screen
data. The odds ratios of those studies were all adjusted
for self-selection bias using the relative rate of breast can-
cer deaths among non-attenders in the screening group
versus those in the control group, estimated from the
RCTs (Duffy et al., 2002 [6]). This adjustment is at bestapproximate as the RCTs of screening took place many
years ago, in countries other than the UK, and any deci-
sion to participate in screening was made in the ab-
sence of evidence regarding the benefits and harms of
screening.
Data from demographic and cohort population studies
were recently used to provide estimates of overdiagnosis
in the service screening setting: in England and Wales,
overdiagnosis was estimated to be between 3.3 and 10%
of the expected cumulative incidence from age 50 to 79
in the absence of screening after correction for self-
selection bias and lead-time bias (Paci et al., 2012 [7]).
Evaluation on a large scale is needed to confirm those
bias corrections.
Mortality from breast cancer has been declining in the
UK population since the early 1990s (CRUK, Accessed 28
March 2013 [1]). This fact coincides with the introduction
of both the national screening programme, and new ad-
juvant therapies, and the respective role of those two
factors in mortality reduction is a matter of debate (Cancer
Intervention Surveillance Modelling Network (CISNET)
Breast Cancer Collaborators, 2006 [8]).
In view of the above, there is a need for a large case–
control study to (1) evaluate the effect of the NHSBSP on
primary breast cancer mortality, with improvements to
design and analysis methodology for coping with bias,
notably self-selection bias: we propose to do this by devel-
oping a procedure using data from different cancer
screening programmes. In addition, there is a need to (2)
quantify the relative contributions of screening attend-
ance, tumour attributes and treatment variables on case
fatality in primary breast cancer, (3) assess the effect of
screening attendance on primary breast cancer incidence,
(4) estimate the rate of overdiagnosis due to screening,
and (5) estimate the effect of screening attendance on inci-
dence of advanced stage primary breast cancer. This final
check may firstly give a result earlier than mortality and
therefore confer greater statistical power, and secondly be
used as a check on the mortality result. Inconsistency be-
tween the observed effect on mortality and that on ad-
vanced stage disease will indicate that further work is
required to deal with residual bias.
Meeting the above aims will entail retrieving more
information than in the traditional case–control eva-
luation of screening. It will include live incident cases as
well as dead ones, and diseased controls as well as
disease-free ones. Additional variables such as cancer
treatment, breast tumour pathology, and screening at-
tendance at other national screening programmes will
also be collected.
This will be an ongoing biennial evaluation to ensure
that the programme continues to deliver the anticipated
health benefit, and to potentially improve the programme
by identifying good and bad practices.
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Study design & objectives
This study is comprised of two sets of retrospective
matched case–control studies: the first set involves dead
cases of primary breast cancer (cases A), and the second
set, recently diagnosed (or incident) cases of primary
breast cancer, dead or alive (Cases C). The dead cases
will be matched with two different sets of controls: two
general population controls who were alive at the case’s
date of death (Controls B), and one diseased control
who was alive at the case’s date of death and had had in-
vasive primary breast cancer (screen-detected, interval
and never screened will all be included) at the case’s date
of first diagnosis (Controls E). The incident cases will be
matched to two controls from the general population
(Controls D). Subsets of cases and matched controls will
be selected for the purpose of each case–control evalu-
ation objective (see Participants: Selection of cases &
controls for details).
Case–control study 1 (CC1) will be a matched com-
parison of the breast cancer dead cases (A) with the gen-
eral population controls (B) with respect to screening
exposure strictly prior to the case’s date of first diagnosis
(set as pseudo-diagnosis date in controls). There will be
two controls per case. This design should allow the
evaluation of screening exposure modalities in relation
to mortality from breast cancer.
Case–control study 2 (CC2) will be a matched com-
parison of the breast cancer dead cases (A) with the dis-
eased controls (E) with respect to screening exposure
strictly prior to the case’s date of first diagnosis (set as
pseudo-diagnosis date in controls). There will be one
control per case. This design should enable assessment
of the interplay between screening attendance, tumour
attributes and treatment variables on fatality from breast
cancer.
Case–control study 3a (CC3a - Incidence) will be
a matched comparison of recently diagnosed/incident
invasive breast cancer cases (C) with the general popu-
lation controls (D) free of invasive disease with respect
to screening exposure strictly prior to the case’s date of
index diagnosis (set as pseudo-diagnosis date in con-
trols). There will be one or two controls per case. This
design should allow the evaluation of screening attend-
ance in relation to breast cancer incidence.
Case–control study 3b (CC3b - Overdiagnosis) will
be a matched comparison of recently diagnosed/incident
invasive and in situ breast cancer cases (C) with the gen-
eral population controls (D) free of invasive and of
invasive or in situ disease, respectively, with respect to
screening exposure strictly prior to the case’s date of
index diagnosis (set as pseudo-diagnosis date in con-
trols), and will be stratified by age at diagnosis/pseudo-
diagnosis. There will be one or two controls per case.This design should allow the evaluation of overdiagnosis
due to screening attendance.
Case–control study 4 (CC4) will be a matched com-
parison of recently diagnosed/incident advanced stage
breast cancer cases (C) with the general population con-
trols (D) free of advanced stage disease with respect to
screening exposure strictly prior to the case’s date of
index diagnosis (set as pseudo-diagnosis date in con-
trols). There will be one or two controls per case. This
design should allow the evaluation of screening attend-
ance on incidence of advanced stage breast cancer. In
principle, one should include all advanced breast cancers
as cases, i.e. whether advanced at diagnosis or whether
subsequently progressed to advanced; however, in prac-
tice it will not be possible to identify those that subse-
quently progress. This analysis will be compared to the
analysis of fatal breast cancers to see whether advanced
breast cancer can be used as a surrogate endpoint when
studying the impact of breast screening on breast cancer
mortality.
An overview of the proposed case–control studies and
corresponding populations are presented in Figure 1.
Setting & source population
The background, implementation and organisation of
the NHSBSP are described in detail elsewhere (Advisory
Committee on Breast Cancer Screening, 2006 [9]). For this
study, all women who were invited to participate in the
breast screening programme in England (from 1988 on-
wards), and who did not express dissent to their records
being used for evaluation purposes, will be targeted.
The evaluation will begin with a pilot phase in colla-
boration with the Knowledge & Intelligence team London,
KIT London (formerly Thames Cancer Registry), using
cases that died from or were diagnosed with breast cancer
between 1st of January 2008 and 31 of December 2009 in
London. The main phase of the study will then be under-
taken, which will cover the whole of England or, in the case
of CC2, those regions (i.e. previous cancer registries) for
which tumour attributes and treatment variables will be
available from 1st of January 2010 - in collaboration with
the Office for National Statistics (ONS). Each main phase
evaluation will cover a 2-year period.
Participants: selection of cases & controls
CC1 & CC2
Population of dead cases (A) All women who died of pri-
mary breast cancer (as stated in part 1 of the death cer-
tificate) age 47–89, within the specified 2-year study
period will be selected. Cases of women with only in situ
primary breast cancer records (i.e. no invasive record)
will be included, but Death Certificate Only (DCO) cases
will be excluded. Case A women will have had their date
Figure 1 Overview of the case–control study designs. Legend: Thick circles, cases; Thin circles, controls; Full border, individuals with cancers;
Dotted border, general population individuals, most of whom have not had cancer, but may have had DCIS or Early Stage Cancer2). ^ Match on
date of birth within 1 month either side; 2 controls per case. * Match on date of birth within 1 month either side; 1 control per case. # Match on
date of birth within 1 month either side, date of first diagnosis within 2 months prior to and including the case’s date of first diagnosis; 1 control
per case. 1Advanced stage is defined as lymph node positive or tumour size >20 mm or both. 2Early stage is defined as lymph node negative,
and tumour size ≤20 mm.
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vasive) age 47–89 and since 1990, and for subsequent
phases of this evaluation (main phase onwards), they will
not have been included as cases in previous evaluation
periods, although they may have been included as con-
trols, and may also be selected as a case C in the same
evaluation.
Population of cases A-matched general population con-
trols (B) For each case A, two women will be selected
among the general population in the Health & Social
Care Information Centre (HSCIC) database at Exeter
who, are registered in the same National Health Applica-
tions and Infrastructure Services (NHAIS) system as the
case at the case’s date of first diagnosis, are alive at the
case’s date of death, and were born within 1 month ei-
ther side of the case’s date of birth. Control B women
may have had primary breast cancer (in situ or invasive)
at the case’s date of first diagnosis. For subsequent
phases of this evaluation (main phase onwards), they will
not have been included as population controls B, E, or D
in previous evaluation periods, although they may be
included as a controls E or D within the same evalu-
ation period.
Population of cases A-matched diseased controls (E)
For each case A, one woman will be selected among the
CR population who was alive at the case’s date of death,and was born within 1 month either side of the case’s
date of birth. DCO cases will be excluded. Control E
women will have had primary invasive breast cancer di-
agnosed within 2 months prior to and including the
case’s date of first diagnosis and: this is necessary to en-
sure that the control survived for at least as long as the
cases. She will have been registered in the same Cancer
Network (CN) at the case’s date of first diagnosis. If no
control E is found using this criterion, the date range
will be expanded to 3 months prior to the case’s date of
first diagnosis (or 6 months prior, if the case’s age at first
diagnosis is less than 50 or over 70). For subsequent
phases of this evaluation (main phase onwards), they
may have been included as population controls B or D
in previous or within the same evaluation periods, and
may be included as a case C within the same evaluation
period.
CC3a, CC3b & CC4
Population of incident cases (C) All women who have
had primary breast cancer (in situ or invasive), diag-
nosed age 47–89 within the specified 2-year study period
will be selected. The index diagnosis will be either a
first or a subsequent tumour and, therefore, women may
have had a previous history of in situ or invasive primary
breast cancer (i.e. prior to the date of their index
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breast cancer (as stated in part 1 of death certificate) age
47–89 during the specified 2-year study period, or after-
wards. Cases of women with in situ primary breast
cancer records only (i.e. no invasive record) will be in-
cluded, but DCO cases will be excluded. For subsequent
phases of this evaluation (main phase onwards), they will
not have been included as cases in previous evaluation
periods, although they may have been included as con-
trols, and may also be selected as a case A in the same
evaluation.
Population of cases C-matched general population con-
trols (D) For each case C, two women will be selected
from the general population in the HSCIC database at
Exeter who, are registered in the same NHAIS system as
the case at the case’s date of index diagnosis, are alive at
case’s date of index diagnosis, and were born within
1 month either side of the case’s date of birth. For subse-
quent phases of this evaluation (main phase onwards),
they will not have been included as population controls
B, E, or D in previous evaluation periods, although they
may be included as controls B or E within the same
evaluation period.
Incident cases (C) and matched general population
controls (D) will be selected a posteriori by the PRU,
using tumour information, to suit the purpose of each
case-study (see Figure 1).
For CC3a, incident cases (C) will be restricted to
those women with invasive breast cancer, and matched
general population controls (D) will be restricted to
those women who have never had invasive primary
breast cancer, but may have had in situ primary breast
cancer prior to and including the case’s date of index
diagnosis.
For CC3b, all incident cases (C) will be selected. For
in situ cases, matched general population controls (D)
will be restricted to those women who never had pri-
mary breast cancer (in situ or invasive) prior to and
including the case’s date of index diagnosis; for invasive
cases, to those women who never had invasive primary
breast cancer, but may have had in situ primary breast
cancer.
For CC4, incident cases (C) will be restricted to those
women with advanced stage (defined below) primary
breast cancer, and matched general population controls
(D) will be restricted to those women who have never
had advanced stage primary breast cancer, but may have
had in situ or early stage primary breast cancer prior to
and including the case’s date of index diagnosis. Breast
cancer will be defined as “advanced stage” if tumour size
is larger than 20 mm, or if at least one regional lymph
node is affected, or if both, and as “early stage” if tumour
size is equal to or smaller than 20 mm and no regionallymph node is affected. For the purpose of data collec-
tion, we have used an inclusive definition of “advanced
stage”, but we will also analyse the data by Stage to as-
sess the association between screening and metastatic
breast cancer for instance, and using only those cases
which are node positive, as this is generally accepted as
an important prognostic factor and as a predictor of the
effect of screening on mortality (Smith et al., 2004 [10]).
If no matched control is found for a particular case (A
or C) with a date of birth within 1 month either side of
the case’s date of birth, the range will be expanded to
3 months either side (or 6 months either side if the
case’s age at index diagnosis of primary breast cancer is
under 50 or over 70).
All cases and controls will appear on the HSCIC data-
base at Exeter. We will aim to select female cases and
controls who have been registered with the NHS by age
47 (determined by either date of first registration on
local NHAIS system or prior cervical/bowel screening
history), and have had available data on both breast and
cervical (for women aged 47–64), and, possibly bowel
(for women aged 60–69) screening strictly prior to their
date of first diagnosis/pseudo-diagnosis (that is, they
have been invited to screening at least once), although
this may not be practicably feasible for dead cases and
matching controls with older age at death. Patient breast,
cervical, and bowel (for the main phase) screening history,
primary breast tumours attributes and treatment data
will be retrieved for all cases and controls, as well as
deprivation quintile.
A detailed description of the algorithm to be used for
the selection of cases and controls is available from the
authors.Data sources & collection
Dead cases (A) and matching diseased controls (E) will be
extracted by KIT London, and matching general popula-
tion controls will be retrieved by the HSCIS at Exeter. Re-
cently diagnosed cases will be extracted by KIT London,
and matching general population controls will be retrieved
by the HSCIS at Exeter. Tumour pathology variables will
be obtained from the National Cancer Data Repository
(NCDR) via KIT London, but may only be available for
certain regions (i.e. previous cancer registries). Breast
screening data will be obtained, as for cervical and bowel
screening variables, from the HSCIS. Bowel screening var-
iables will not be sought for the pilot phase.
The data will be checked and cleaned by the PRU
Senior Data Manager, transferred to separate Oracle tables,
and stored on a UNIX server kept in a secure server
room within the Wolfson Institute of Preventive Medi-
cine. Access to the Oracle database is from PCs on the se-
cure QMCR network using SQLNET.
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Information Governance guidelines.
Variables
A list of all the variables to be retrieved during the on-
going evaluation study is presented in Table 1.
Information retrieved regarding living area on which
to match cases and controls will vary depending on the
study (pilot or main phase) and time of evaluation.
NHAIS information will be obtained from HSCIC for
Health for all cases and controls used for CC-1, CC-3a/b
and CC-4 studies, while CN information will be used by
KIT London to match cases and controls for CC-2.
Study size / Power calculation
The main phase of the study will cover the whole of
England with biennial accrual of potentially thousands of
cases (circa 18,000 (CRUK, Accessed 28 March 2013
[1])), for which statistical power will not be an issue for
any of the case studies, and for which there will be con-
siderable precision. The large sample size will also allow
subset evaluation, notably by time since last screen. The
sample size for the pilot study was estimated to enable
sufficient power to answer the primary objectives ad-
dressed by CC1 and CC2 with relative confidence. Re-
sults of the pilot with respect to CC3a, CC3b and CC4
objectives will provide the prior estimates currently lack-
ing to perform power calculations.
CC1. For the matched comparison of the breast can-
cer dead cases (A) with the general population controls
(B), assuming an odds ratio of 0.7 for the event of ever
attending screening (Broeders et al., 2012 [11]), around
900 dead cases and 1800 living controls would conferTable 1 Variables of interest
Patient characteristics Primar
(all pri
Patient unique ID Tumou
NHS number Tumou
Gender ICD10 c
Case or Control Date of
Date of birth Tumou
Patient status (alive or dead at end of study period) Treatm
Cause of death – Breast cancer (where applicable) Tumou
Date of death (where applicable) Numbe
Age at death (where applicable) Stage
Date of tumour diagnosis / pseudo-diagnosis Grade
Age at tumour diagnosis / pseudo-diagnosis
Cancer registry
Geographical area
IMD (Postcode-based)90% power to detect such an effect size at the 5% signifi-
cance level when using a 2-sided test (Machin et al.,
1997 [12]).
CC2. For the matched comparison of the breast can-
cer dead cases (A) with the diseased controls (E), no es-
timate of the odds ratio is available, but it can be
assumed to be 0.70 or less for the event of ever attend-
ing screening, to be at least consistent with CC1. With
only one control per case, 1200 / 900 dead cases and the
same number of controls will be required to obtain 90%
and 80% power, respectively.
Missing data for some of the breast tumour attributes
and treatment can be close to 40-50%, and the pilot
sample size will be inflated accordingly. Sensitivity ana-
lyses will be conducted for various possible scenarios of
non-random missing status.
We are therefore planning to collect pilot data from
at least 1400 dead cases (A), together with 2800 gen-
eral population controls (B) and 1400 diseased controls
(E) matched for these. We will also collect at least
1400 recently diagnosed cases (C) and 2800 general
population matched controls (D). There will be some
degree of overlap between populations (A, C), (C, E)
and (B, D).Bias & Effect modification
The case–control design is potentially prone to a num-
ber of biases (Walter, 2003 [5]), in particular some that
could confer a bias in favour of screening, and which are
addressed either at the design stage by choosing appro-
priate selection criteria, or at the analysis stage by using
suitable statistical methods.y breast tumour attributes Screening data
mary breast tumours)
r unique ID NHS registration by age 47
r status (in situ or invasive) Screening office/centre
ode Episode date
tumour diagnosis Screen / Test date
r detection mode Screen / Test outcome
ent
r size
r of lymph nodes
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Among the screen-detected cases who die with primary
breast cancer as a contributing cause on their death cer-
tificate (including DCO cases), there are those who would
have died without any diagnosis of breast cancer, had they
not been screened, forming part of overdiagnosis due to
screening (Duffy, 2010 [13]). This introduces a bias against
screening when assessing the impact of screening attend-
ance on mortality, although unlikely to be a large one. It
will be addressed at the analysis stage by a series of sensi-
tivity analyses, assuming a range of plausible magnitudes
of the bias. This bias may also qualify interpretation of the
results from an analysis assessing the impact of time since
last screen on the case–control status among screen-
detected cancer patients.
In contrast, women with multiple co-morbidities who
may be less likely to have breast cancer recorded as
cause of death may be less likely to be screened. Conse-
quent exclusion of those women from our datasets
would confer a bias against screening.Exposure (screening) opportunity bias
Once diagnosed with breast cancer, the cases come under
clinical management and do not continue with routine
breast screening as before. The controls, however, may
continue to attend screening up to the time of the case be-
ing entered into the study. This potential bias is addressed
at the design stage by giving the controls a pseudo-
diagnosis date that is the same as that of their matched
case and screening history is only considered up to that
date (Connor et al., 2000 [14]). This is in fact an over-
correction and results in a bias against screening. The fact
of the case having necessarily a diagnosis of breast cancer
and a control usually not having such a diagnosis, induces
an artificially higher retrospective probability of screening
exposure in the cases, a bias against screening (i.e. the
screen-detected cases will always have this screen re-
corded at diagnosis, whereas the large majority of controls
will not at pseudo-diagnosis). Simply excluding the detec-
tion screens from the histories would bias the results in
favour of screening. When assessing the effect of ever hav-
ing been screened, the major driver of this bias is pre-
valence screening, and for a mature programme with
approximately 6 incidence screens for each prevalence
screen, this bias is likely to be small. However, this bias
may remain when using other measure of screening ex-
posure. The extent of screening opportunity bias will be
investigated by applying an analytical correction to the
odds ratio using the method by Duffy et al., 2008a [15],
and by performing sensitivity analyses in which the date of
pseudo-diagnosis for controls will be extended by up to
4 years, the estimated average sojourn time for each
screen-detected case, to counteract the artificially higherretrospective probability of screening exposure in cases
(Connor et al., 2000 [14]).
But the major sources of bias in case–control studies
are potential self-selection and lead-time biases (Puliti
et al., 2011 [16]). Length bias will also be discussed. Note
that lead-time and length biases will only affect analyses
assessing the effect of screening on survival among cases
(i.e. case-study 2), but not those assessing its impact on
population outcomes (incidence or mortality).
Self-selection bias (or non-compliance bias)
Women who accept the invitation to screening (attenders)
may have an a priori better health status (and a lower
underlying risk of dying from breast cancer) compared
with women who do not (non-attenders), and therefore
are less likely to die from the disease. We would anticipate
that this will confer a bias in favour of screening. Although
this bias in favour of screening is unavoidable at the design
stage, it can be approximately corrected for in the statis-
tical analysis. In women diagnosed with breast cancer aged
47–52 (and their controls) we will look at two factors: “(in-
vited and) screened”, “invited but not screened” compared
to “not invited”. The odds ratio in “invited but not
screened” can be used to adjust for the self-selection bias
using the method by Duffy et al. (2002) [6]. This method
cannot be used in older women as they will all have been
invited.
The method developed by Duffy et al. (2002) [6] will also
be used to correct the estimated odds ratio using data on
participation in the NHSCSP (cervical) and/or NHSBCSP
(bowel) screening programmes, rather than data on partici-
pation from the RCTs of mammographic screening. In the
absence of self-selection, the relative risk of primary breast
cancer (death/incidence) associated with breast screening
for non-attenders at cervical or bowel screening would be
expected to be equal to the relative risk in cervical or
bowel screening attenders (after adjusting for breast cancer
screening). In practice, the relative risk of primary breast
cancer has been shown to be about 10% lower in non-
attenders to RCTs (Duffy et al., 2002 [6]). The crucial elem-
ent in correcting for self-selection bias is the risk ratio
(termed “Dr”) for non-attenders versus attenders to cer-
vical or bowel screening. This will be calculated for women
who attended breast screening at least once and for women
who did not attend a single screen, to control for attend-
ance at breast screening. A range of denominator values
for “Dr” will be assessed for sensitivity. One could compare
primary breast cancer rates (i) in women who have had
bowel/cervical screening - but not breast screening -with
women who have had neither bowel/cervical nor breast
screening; and (ii) in women who have had both bowel/cer-
vical and breast screening with women who have only had
breast screening. Data for women with age at diagnosis/
pseudo-diagnosis between 47 and 64 year-old who would
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programmes will be used. Alternatively, data for women
with age at diagnosis/pseudo-diagnosis between 60 and
69 year-old who would have been invited to both the breast
and bowel screening programmes will be used. Also, in
women under age 50, one could compare primary breast
cancer rates in women who have, or have not had, cervical
screening, hence by-passing the positive confounding be-
tween uptake of the various screening programmes.
Breast screening coverage of women aged 53–70 in
England was 77% at 31st March 2012 (The HSCIC
Breast Screening Programme – England report, 2011-
2012 [17]).
In addition, self-selection will be addressed at an indi-
vidual woman level by adjusting the regression model
for participation in the other screening programmes,
with careful adjustment for the confounding between at-
tendances in different programmes: participation will be
recorded as “Currently screened”, “Formerly screened”
and “Never screened”, enabling all women to be in-
cluded in the analysis.
For the pilot phase, a single self-selection factor will be
estimated as the data covers one Strategic Health Authority
(SHA) only (London); for the national phase, regional
factors may be estimated to assess variation in self-
selection between regions. This approach will be com-
pared with adjusting the regression model for potential
confounders, such as history of cervical/bowel screening,
and socioeconomic (SEC) status. The Index of Multiple
Deprivation (IMD) is an area-based measure of relative
deprivation, derived from the womens’ postcodes based
on census statistics for overcrowded housing and other
factors, and is believed to be the main confounding factor
relating to both the exposure (i.e. the decision to attend
screening), and the outcome.Lead-time bias
Lead-time is the amount of time by which the date of
diagnosis has been advanced by screening detection as
opposed to symptomatic occurrence. This confers a bias
in favour of screening, which will be addressed at the
analysis stage of case study 2 using two approaches: (1)
“postponement of screen-detected cases” where the date
of diagnosis for the screen-detected cases will be shifted
forward for a period corresponding to the estimated
lead-time (Gabe et al., 2007 [18]), and (2) statistical ad-
justment where the cases’ (and diseased controls, where
applicable) additional follow-up time (between date of
diagnosis and date of death/censor date) - observed
purely as a result of lead-time - will be estimated by as-
suming an exponential distribution of the sojourn time,
the period during which the tumour is asymptomatic
but screen-detectable (Duffy et al., 2008b [19]). Theestimates for mean sojourn time will be taken from
Tabar et al. (2000 [20]).
Applying a restriction on the date of diagnosis during
the selection of dead cases can also introduce a form of
lead-time bias. Among cases who died from breast cancer
on the same date, the screen-detected ones would have re-
ceived their diagnosis earlier than the symptomatically-
diagnosed cases, and therefore would tend to be excluded
during the selection, introducing a bias in favour of
screening. No restriction on the case’s date of diagnosis
will be applied at the design stage, i.e. all women diag-
nosed after the inception of the NHSBSP, i.e. since 1990,
will be included in the study.
Length bias
Length-biased sampling occurs when the chance of an ob-
servation being in a sample is proportional to a particular
characteristic of the observation. In the context of screen-
ing, length bias is the phenomenon whereby slower-
growing, less aggressive tumours (including DCIS) have a
longer pre-clinical screen-detectable period (PCDP) and
are therefore more likely to be screen-detected compared
to faster-growing, more aggressive cancers. This will con-
fer a bias in favour of screening, which will be addressed at
the analysis stage of case-study 2 by performing sensitivity
analyses. Two latent tumour populations will be assumed,
one – the “length bias group” - with both a higher prob-
ability of being screen-detected and a correspondingly
lower probability of fatality, whether actually detected by
screening or symptomatic (Duffy et al., 2008b [19]).
The extreme form of length bias is overdiagnosis, defined
as the diagnosis of cancers which would not have come to
clinical attention in the patient’s lifetime had screening not
taken place. Overdiagnosis can be estimated by comparing
cumulative incidence in screened and unscreened popula-
tions several years after screening stops (Biesheuvel et al.,
2007 [21]). Estimates of overdiagnosis obtained from ob-
servational studies vary widely according to the design
used, i.e. dynamic populations or cohort populations (Puliti
et al., 2011 [16]). In case–control studies, which are nested
within a cohort population, overdiagnosis can be robustly
estimated provided that (1) the difference in underlying
risk of primary breast cancer between screened and un-
screened populations (i.e. self-selection bias), and (2) the
period of time by which the diagnosis is brought forward
by screening (i.e. lead-time bias) are both accounted for
(Duffy et al., 2010 [13], Puliti et al, 2011 [16]). In the ab-
sence of overdiagnosis, the initial increase in primary
breast cancer occurrence in the screened group would be
fully compensated by a similar decrease in cancers among
older age groups no longer offered screening (“compensa-
tory drop method”, Puliti et al., 2011 [16]).
In addition to investigating the extent of the different
biases when examining the relationship between screening
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that may (positively or negatively) modify the effect of the
screening exposure on the outcome (effect modifiers), such
as age at diagnosis / pseudo-diagnosis (5-year band), epoch
of diagnosis (5-year band), and tumour detection mode of
the cases will be of interest.
Statistical methods
All case–control study analyses will be conducted using
conditional logistic regression. Matching factors (i.e.
age, area) are controlled for in the design. All statistical
analyses will be performed using the statistical software
STATA or R.
CC1. The primary objective of this case–control will be
to assess the effect of various measures of attendance at
breast screening strictly prior to the case’s date of first
diagnosis/ the control’s date of pseudo-diagnosis on mor-
tality from primary breast cancer. The primary measure of
attendance to screening will be whether a woman ever
attended at least one screen episode (indicator variable).
Secondary measures will be:
 the total number of screens (counts);
 the time since last screen (continuous variable), and
whether that time span fell within the past three
years (≤ 3 years or > 3 years), as this corresponds to
the NHSBSP protocol and approximates the
estimated PCDP;
 the time since penultimate screen (continuous or
categorical);
 the interval between last screen and penultimate
screen (continuous or categorical);
 the maximum interval between 2 screens
(continuous or categorical);
 the average interval between 2 screens (continuous
or categorical);
 the patient’s age at first screen (continuous or
categorical);
 the patient’s age at last screen.
Ascertainment, self-selection and exposure opportunity
biases will be addressed using the methods described in
the Bias & Effect modification section.
Secondary objectives will consider time since last
screen stratified by age at diagnosis/pseudo-diagnosis, by
first tumour detection mode, and by region (Main phase
only).
The effect of attending a screen in a particular 3-year
age band in the main phase (such as 47–49 inclusive), or
5-year age band in the pilot phase, on mortality from
primary breast cancer in the subsequent 5-year age band
(such as 50–54) will also be investigated, as performed
for the cervical screening audit (Sasieni et al., 2009 [22]).
The results of this analysis should be very similar tothose obtained from the analysis of “time since last
screen” after stratifying the analysis by age at diagnosis/
pseudo-diagnosis.
CC2. The primary objective of this case–control will be
to estimate the proportional effects of screening attend-
ance strictly prior to date of diagnosis/pseudo-diagnosis
and cancer treatment, on prognosis in patients diagnosed
with primary breast cancer. The primary and secondary
measures of attendance to screening will be as for CC1; in
addition, they will include tumour detection mode to as-
sess the relationship between detection mode and choice
of cancer treatment.
The regression analysis will be adjusted for tumour at-
tributes such as stage of disease at diagnosis and other
pathological features. Because of the extreme collinearity
between cancer treatment and pathology variables, e.g.
lymph node positivity, a major determinant of treatment
choice, estimating relative effects from the regression
analysis often gives unreliable/biased estimates of cancer
treatment (Wishart et al., 2010 [23]). To address this
statistical issue, a counterfactual analysis will be per-
formed (Höfler et al., 2005 [24]). The treatment that an
individual actually does not receive is called counterfac-
tual treatment, and the outcome under this treatment,
after treatment assignment, is referred to as counterfac-
tual outcome. In our study, the cancer treatment effects
will be constrained to the absolute effect estimated from
meta-analyses of the RCTs.
Self-selection, lead-time, and length biases will be ad-
dressed using the methods described in the Bias & Effect
modification section. Because in CC2, both cases and con-
trols have had primary breast cancer, exposure opportunity
bias can be assumed to be minimal.
Secondary objectives will consider time since last
screen stratified by epoch of diagnosis to further explore
collinearity among the explanatory variables.
CC3a/b. The primary objectives of these case-controls
will be to estimate the effect attendance at breast screen-
ing strictly prior to date of diagnosis/pseudo-diagnosis
on incidence of invasive (CC3a) or, of in situ and inva-
sive (CC3b) primary breast cancer, and to estimate rates
of overdiagnosis due to screening.
The primary and secondary measures of attendance to
screening will be as for CC1, in particular time since last
screen; in addition, they will include the patient’s age at
last screen, and whether a woman ever missed attend-
ance at recall assessment(s). This last measure should
help assess potential room for improvement in the man-
agement of suspicious screening results.
With time since last screen, one might expect an ob-
served increase in incidence (excess risk) immediately
after a screen (the screen-detected cases), followed by an
observed decrease in incidence (deficit in risk) due to the
removal of pre-clinical cases by the screen. The deficit
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screen. The analysis will be stratified by age at diagnosis/
pseudo-diagnosis. Indeed, one might expect an excess risk
of disease in screened ages (within screening age range)
and a deficit in risk in non-screened ages (above screening
age range); a potential deficit in risk may also be seen at
later ages within the screening age range (i.e. at age 65–69
after up to 15 years of screening). In the absence of overdi-
agnosis, the initial excess risk from screening would be
fully compensated by a deficit in risk over time in the ab-
sence of screening (“compensatory drop”, Puliti et al.,
2011 [16]). The excess risk in screened ages and the deficit
in risk in non-screened ages will be quantified and com-
bined with National Incidence Rates to construct risk
scores (Field et al., 2005 [25]) in an attempt to estimate
lifetime effect of screening on incidence and overdiagnosis.
As the NHSBSP has been running for at least 20 years,
there should be sufficient follow-up data after screening
stopped (age 70), and the method of “compensatory drop”
should achieve full adjustment for lead-time (Puliti et al.,
2011 [16]). If the pilot phase of the study highlights little
or no follow-up after last screen, lead-time bias will be
adjusted using the “postponement of screen-detected
cases” method (described in the Bias & Effect modification
section).
The estimations will be performed for all disease (in
situ and invasive) and for invasive disease only.
Self-selection and exposure opportunity biases will be
also addressed using the methods described in the Bias
& Effect modification section.
Secondary objectives will consider time since last
screen stratified by region (Main phase only).
CC4. The primary objective of this case–control will
be to estimate the effect of attendance to breast screen-
ing strictly prior to date of diagnosis/pseudo-diagnosis
on incidence of advanced stage primary breast cancer.
The primary and secondary measures of attendance to
screening will be as for CC1; in addition, they will in-
clude age at last screen.
Self-selection and exposure opportunity biases will be ad-
dressed using the methods described in the Bias & Effect
modification section.
Secondary objectives will consider time since last
screen stratified by age at diagnosis/pseudo-diagnosis, and
by region (Main phase only). Analysis may be adjusted for
stage at diagnosis.
Results from CC1 and CC3 analyses will be combined
with published data on breast cancer mortality and inci-
dence over time, respectively, to estimate projected mortal-
ity, projected incidence, and stage-specific incidence in the
presence and absence of screening and derive prevented
fraction as an impact measure to help interpretation and
evaluation of the programme benefits harms (Independent
UK Panel on Breast Cancer Screening, 2012 [26]).Ethics
The study protocol was reviewed and approved by the UK
department of health. Ethical approval was obtained from
the London Research Ethics Committee (REC) of the Na-
tional Research Ethics Service (NRES) (reference number
12/LO/1041), and by the National Information Govern-
ance Board NIGB) Ethics and Confidentiality Committee
(ECC) (Reference number ECC 6–05 (e)/2012). Both orga-
nisations are now merged into the Confidential Advisory
Group (CAG).
The study has received from the National Institute
for Health Research Clinical Research Network (NIHR
CRN) support, and has been provisionally assigned to the
National Cancer Research Network (NCRN) (UKCRN
Study ID = 14978, http://public.ukcrn.org.uk/search).Discussion
This protocol aims to evaluate the policy of mammog-
raphy screening as delivered in the current NHSBSP in
terms of, benefits on mortality from and on incidence of
invasive primary breast cancer, and, harms from overdiag-
nosis. In the post-RCT epoch, analytical observational
studies are the design of choice. The attraction of the
case–control evaluation strategy resides in that, (1) it dir-
ectly relates the clinical endpoint to the screening history
at an individual level, (2) being retrospective in design it
requires no further follow-up and is therefore quick to
perform, and finally, (3) it needs a relatively small number
of cases and corresponding controls. In addition, the
case–control design allows the assessment of what actually
happened in the population during service screening, tak-
ing into account natural variation. It also has the flexibility
to question aspects of the screening regime which were
not possible to address using RCT data. The case–control
design is potentially prone to a number of biases, in par-
ticular some that could confer a bias in favour of screen-
ing. However, with careful design and analysis, one can
minimize the risk of biased results. The case–control de-
sign proved indeed to be a powerful tool in the evaluation
of the NHS Cervical Screening Programme, informing
policy on screening intervals and age ranges (Sasieni et al.,
2009 [22]).
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